Gonadorelin
Gonadorelin (GnRH) is the bioidentical, synthetic equivalent of Gonadotropin-Releasing Hormone, functioning as the absolute cornerstone of the Hypothalamic-Pituitary-Gonadal (HPG) axis. In anti-aging protocols and Endocrinology, it has largely replaced hCG to preserve testicular volume, maintain high-quality spermatogenesis, and uphold endogenous testosterone production in men undergoing aggressive systemic TRT. Its half-life is excruciatingly short, meaning it demands highly calculated, pulsatile dosing schedules to aggressively stimulate, rather than accidentally suppress, the hormonal cascade.
Quick Stats
Scientific Data
Mechanism of Action
Gonadorelin is a bioidentical synthetic version of the naturally occurring Gonadotropin-Releasing Hormone (GnRH/LHRH). It is a decapeptide that acts on anterior pituitary gonadotroph cells to stimulate pulsatile release of both LH (luteinizing hormone) and FSH (follicle-stimulating hormone).
In pulsatile administration, gonadorelin maintains and restores the hypothalamic-pituitary-gonadal (HPG) axis. It is prescribed alongside TRT (testosterone replacement therapy) to preserve fertility and testicular function. Continuous (non-pulsatile) administration paradoxically suppresses LH/FSH through GnRH receptor downregulation — this is exploited clinically by GnRH agonists like leuprolide for prostate cancer and endometriosis treatment.
Source: PMID: 1903034
Background & History
Gonadorelin is the synthetic form of endogenous GnRH (Gonadotropin-Releasing Hormone), a decapeptide produced in the hypothalamus that drives pulsatile release of LH and FSH from the pituitary. It was first synthesized and characterized by Andrew Schally and Roger Guillemin in 1971, earning them the 1977 Nobel Prize in Physiology or Medicine. Pulsatile gonadorelin maintains testicular function and testosterone production during androgen therapy by preserving the HPG axis — specifically preventing the testicular atrophy and infertility caused by exogenous testosterone.
Research Use Cases
- ✓HPG axis preservation during testosterone replacement therapy (TRT)
- ✓Male infertility treatment via LH/FSH stimulation
- ✓Post-cycle therapy (PCT) to restore natural testosterone production
- ✓Female fertility stimulation in hypothalamic amenorrhea
Dosing Protocol
| Typical Dose | 100-500 mcg/day |
| Frequency | 1-2× daily |
| Half-Life | ~4 minutes |
| Common Vial Sizes | 2 mg |
Dosing Protocols
TRT Co-Administration
PCT / Restart Protocol
Body-Weight Dosing Reference
Estimated doses extrapolated from the published research range of 100–500 mcg/day (referenced to 70 kg / 154 lb). These are approximations — consult a qualified healthcare provider for personalised guidance.
| Weight | Low Dose | Target Dose | High Dose |
|---|---|---|---|
| 120 lb(54 kg) | 77 mcg | 231 mcg | 386 mcg |
| 140 lb(63 kg) | 90 mcg | 270 mcg | 450 mcg |
| 160 lb(73 kg) | 104 mcg | 313 mcg | 521 mcg |
| 180 lb(82 kg) | 117 mcg | 351 mcg | 586 mcg |
| 200 lb(91 kg) | 130 mcg | 390 mcg | 650 mcg |
| 220 lb(100 kg) | 143 mcg | 429 mcg | 714 mcg |
| 250 lb(113 kg) | 161 mcg | 484 mcg | 807 mcg |
💉 For exact syringe units based on your vial concentration, use the Gonadorelin Reconstitution Calculator →
Administration
Expected Timeline
Who Is It For?
TRT Fertility Preservation
HighGold standard for maintaining HPG axis during TRT. Prevents testicular atrophy and preserves fertility.
Post-Cycle Therapy (PCT)
HighPulsatile dosing restarts LH/FSH production after suppression. FDA-approved (Factrel) with decades of data.
Reconstitution Example
Safety & Considerations
FDA-approved (Factrel) for diagnostic use with excellent safety profile. Must be administered in pulsatile fashion — continuous use will paradoxically suppress the HPG axis. Injection site irritation is the most common side effect.
Regulatory & Legal Status
FDA-approved as Factrel®; widely used off-label as Gonadorelin Acetate in TRT protocols
Competitive athletes subject to anti-doping controls should not use Gonadorelin.
Compounded Drug (Rx)
US Compounding: Available via licensed pharmacy Rx
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Interactions & Contraindications
Pulsatile administration (every 60-90 min) is required for efficacy — continuous infusion paradoxically suppresses LH/FSH (basis of GnRH agonist therapy for prostate cancer). Depot formulations of GnRH agonists (leuprolide, histrelin) work by this paradoxical suppression mechanism. Antiandrogens blunt downstream testosterone response.
Synergies & Common Stacks
Kisspeptin acts upstream of GnRH — it's the master activator of GnRH neurons. Combining both ensures complete HPG axis stimulation from hypothalamic to pituitary to gonadal level.
Dosing Quick Reference
Frequently Asked Questions
Why is gonadorelin used with TRT?▼
How often should gonadorelin be injected?▼
References
- Schally AV et al. “"Gonadorelin (GnRH) in clinical practice".” Endocrine Reviews (1980). PMID: 6774397
📚 Related Articles
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code